Jnci Journal of the National Cancer Institute

NOV 5, 2026 · JOURNAL ARTICLE

Treatment-related neutropenia as predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Jnci Journal of the National Cancer Institute

BACKGROUND: Prior analyses of PALLAS (NCT02513394), a phase III trial that randomized patients with stage II-III hormone receptor-positive breast cancer to receive adjuvant palboci

OCT 19, 2026 · JOURNAL ARTICLE

Cardio-protection and monitoring for early phase clinical trials: Recommendations from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium

Jnci Journal of the National Cancer Institute

BACKGROUND: Many effective anti-cancer modalities potentially induce cardiotoxicity. Pediatric patients with relapsed/refractory hematologic malignancies are often excluded from an

OCT 9, 2026 · JOURNAL ARTICLE

The early-onset pancreatic cancer paradox: a systematic review and meta-analysis

Jnci Journal of the National Cancer Institute

BACKGROUND: Globally, the rate of early-onset pancreatic cancer (EOPC) is increasing, but its clinical features and outcomes relative to average-onset pancreatic cancer (AOPC) rema

OCT 1, 2026 · JOURNAL ARTICLE

Immunotherapy-Based Therapies in Pediatric Hodgkin Lymphoma: Potential to Narrow the Gap in Long-Term Survival

Jnci Journal of the National Cancer Institute

Abstract Pediatric advanced-stage Hodgkin lymphoma (HL) is highly curable, yet survivors treated with historical regimens face substantial late morbidity and excess mortality. Immu

AUG 8, 2026 · JOURNAL ARTICLE

Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan

Jnci Journal of the National Cancer Institute

Preclinical mechanistic study in cell lines and xenografts proposing a combination strategy; no clinical trial data, no human efficacy endpoints, and no regulatory or phase 1+ evidence to support practice change.